Portal de Periódicos da CAPES

Therapy effect of antiulcer agents on new chronic cysteamine colon lesion in rat

2001; Elsevier BV; Volume: 95; Issue: 1-6 Linguagem: Inglês

10.1016/s0928-4257(01)00039-0

1769-7115

Predrag Sikirić, Sven Seiwerth, Gorana Aralica, Darko Perović, Mario Starešinić, Tomislav Anić, Miroslav Gjurašin, Ingrid Prkačin, Jadranka Šeparović, Dinko Stancic-Rokotov, Martina Lovrić Benčić, Darko Mikuš, Branko Turković, Ivo Rotkvić, Stjepan Miše, Rudolf Ručman, Marijan Petek, Tihomil Žiger, Božidar Šebečić, Zoran Ivasović, Vjekoslav Jagić, Ljiljana Komerički, Ivan Balen, Alenka Boban-Blagaić, Ivo Sjekavica,

Drug Transport and Resistance Mechanisms

After demonstration that cysteamine induced duodenal lesions in gastrectomized rats, while a number of antiulcer drugs mitigated these lesions, it was shown that one single intrarectal (i.r.) cysteamine application produced severe colon lesions in acute studies in rats. Thus, the further focus was on the protracted effect of cysteamine challenge (400 mg/kg b.w. i.r.) and therapy influence in chronic experiments in female rats. Regularly, cysteamine colon lesions were markedly mitigated by ranitidine (10), omeprazole (10), atropine (10), methylprednisolone (1), sulphasalazine (50; mg/kg), pentadecapeptide BPC 157 (PL-10, PLD-116; 10 microg or 10 ng/kg). Specifically, after 1 or 3 months following initial challenge (cysteamine 400 mg/kg i.r.) in female rat, the therapy [BPC 157 (PL-10, PLD-116 (10.0 microg or 10.0 ng/kg; i.g., i.p., i.r.), ranitidine, omeprazole, atropine, methylprednisolone, sulphasalazine (i.p.)] reversed the protracted cysteamine colon injury: the 1 week-regimen (once daily application) started after 1 month post-cysteamine, as well as the 2 weeks-regimen (once daily application), which started after 3 months. The effect on recidive lesion was also tested. These cysteamine lesions may reappear after stopping therapy (after stopping therapy for 3 weeks at the end of 2-weeks regimen started in 3 months-cysteamine female rats) in sulphasalazine group, while this reappearance is markedly antagonized in pentadecapeptide BPC 157 (PL-10, PLD-116)-rats (cysteamine-colon lesion still substantially low).